Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ.

Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067.

PMID:
23306360
2.

A systematic review of the cost effectiveness of herpes zoster vaccination.

Szucs TD, Pfeil AM.

Pharmacoeconomics. 2013 Feb;31(2):125-36. doi: 10.1007/s40273-012-0020-7. Review.

PMID:
23335045
3.
4.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45.

PMID:
18382137
5.

Cost effectiveness of herpes zoster vaccine in Canada.

Najafzadeh M, Marra CA, Galanis E, Patrick DM.

Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

PMID:
19908924
6.

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.

BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.

7.

Cost-effectiveness of vaccination against herpes zoster.

de Boer PT, Wilschut JC, Postma MJ.

Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670. Review.

8.

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.

van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE.

BMC Health Serv Res. 2010 Aug 13;10:237. doi: 10.1186/1472-6963-10-237.

9.

Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.

Le P, Rothberg MB.

Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.

PMID:
26344036
10.

Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.

Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P.

Vaccine. 2012 Jan 11;30(3):675-84. doi: 10.1016/j.vaccine.2011.10.036.

PMID:
22120193
11.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8.

12.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Hornberger J, Robertus K.

Ann Intern Med. 2006 Sep 5;145(5):317-25.

PMID:
16954357
13.

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.

Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N.

Hum Vaccin Immunother. 2015;11(4):884-96. doi: 10.1080/21645515.2015.1011561.

14.

Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.

Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ.

Vaccine. 2014 Mar 26;32(15):1645-53. doi: 10.1016/j.vaccine.2014.01.058. Review.

PMID:
24534737
15.

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

Hum Vaccin. 2011 Jul;7(7):749-56. doi: 10.4161/hv.7.7.15573.

16.

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19.

PMID:
23537397
17.

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA.

Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.

PMID:
19908925
18.

Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.

Johnson RW.

Aging Clin Exp Res. 2009 Jun;21(3):236-43. Review.

PMID:
19571648
19.

Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O.

BMC Public Health. 2015 Jun 5;15:533. doi: 10.1186/s12889-015-1861-8. Review.

20.

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ.

Vaccine. 2009 Feb 25;27(9):1454-67. doi: 10.1016/j.vaccine.2008.12.024.

PMID:
19135492
Items per page

Supplemental Content

Support Center